The suit, which was filed in 2005 by two former Wyeth sales representatives, alleges that Wyeth promoted Rapamune, an immunosuppressant, for use in lung transplants, although it was approved by the FDA for kidney transplants only. Additionally, the suit alleges Wyeth provided cash and other kickbacks to physicians to induce them to prescribe Rapamune. The suit also alleges these violations led to the submitting of false claims to government health programs, according to the report.
Last year, Pfizer paid $2.3 billion to settle an investigation that it promoted off label use of pain drug Bextra and other products.
Read the Wall Street Journal report on the Pfizer kickback suit.
Read more coverage on Pfizer:
